Literature DB >> 9621079

Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors.

L Doyon1, C Payant, L Brakier-Gingras, D Lamarre.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) variants resistant to protease inhibitors have been shown to contain a mutation in the p1/p6 Gag precursor cleavage site. At the messenger RNA level, this mutation generates a U UUU UUU sequence that is reminiscent of the U UUU UUA sequence required for ribosomal frameshifting and Gag-Pol synthesis. To test whether the p1/p6 cleavage site mutation was generating a novel frameshift site, HIV sequences were inserted in translation vectors containing a chloramphenicol acetyltransferase (CAT) reporter gene requiring -1 frameshifting for expression. All sequences containing the original HIV frameshift site supported the synthesis of CAT but expression was increased 3- to 11-fold in the presence of the mutant p1/p6 sequence. When the original frameshift site was abolished by mutation, expression remained unchanged when using constructs containing the mutant p1/p6 sequence, whereas it was decreased 2- to 4.5-fold when using wild-type p1/p6 constructs. Similarly, when introduced into HIV molecular clones, the p1/p6 mutant sequence supported Gag-Pol synthesis and protease activity in the absence of the original frameshift site, indicating that this sequence could also promote ribosomal frameshifting in virus-expressing cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621079      PMCID: PMC110421     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions.

Authors:  R Higuchi; B Krummel; R K Saiki
Journal:  Nucleic Acids Res       Date:  1988-08-11       Impact factor: 16.971

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems.

Authors:  W Wilson; M Braddock; S E Adams; P D Rathjen; S M Kingsman; A J Kingsman
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

4.  A simple phase-extraction assay for chloramphenicol acyltransferase activity.

Authors:  B Seed; J Y Sheen
Journal:  Gene       Date:  1988-07-30       Impact factor: 3.688

5.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.

Authors:  Y M Zhang; H Imamichi; T Imamichi; H C Lane; J Falloon; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo.

Authors:  N T Parkin; M Chamorro; H E Varmus
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.

Authors:  J Park; C D Morrow
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

8.  An RNA pseudoknot and an optimal heptameric shift site are required for highly efficient ribosomal frameshifting on a retroviral messenger RNA.

Authors:  M Chamorro; N Parkin; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15.

Authors:  F D Veronese; R Rahman; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

10.  Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region.

Authors:  T Jacks; H D Madhani; F R Masiarz; H E Varmus
Journal:  Cell       Date:  1988-11-04       Impact factor: 41.582

View more
  30 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure.

Authors:  Jonathan D Dinman; Sara Richter; Ewan P Plant; Ronald C Taylor; Amy B Hammell; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.

Authors:  Elena Knops; Léa Brakier-Gingras; Eugen Schülter; Herbert Pfister; Rolf Kaiser; Jens Verheyen
Journal:  Med Microbiol Immunol       Date:  2011-12-27       Impact factor: 3.402

4.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

5.  HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Authors:  Isabel Olivares; Alok Mulky; Peter I Boross; József Tözsér; John C Kappes; Cecilio López-Galíndez; Luis Menéndez-Arias
Journal:  J Mol Biol       Date:  2007-07-03       Impact factor: 5.469

6.  Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.

Authors:  Lucile Larrouy; Sidonie Lambert-Niclot; Charlotte Charpentier; Slim Fourati; Benoit Visseaux; Cathia Soulié; Marc Wirden; Christine Katlama; Patrick Yeni; Françoise Brun-Vézinet; Vincent Calvez; Anne-Geneviève Marcelin; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 7.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 8.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

9.  Stability of HIV Frameshift Site RNA Correlates with Frameshift Efficiency and Decreased Virus Infectivity.

Authors:  Pablo Garcia-Miranda; Jordan T Becker; Bayleigh E Benner; Alexander Blume; Nathan M Sherer; Samuel E Butcher
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

10.  Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Authors:  Sarah K Ho; Roxana M Coman; Joshua C Bunger; Stephanie L Rose; Patricia O'Brien; Isabel Munoz; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  Virology       Date:  2008-07-02       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.